GT-002(Glycotope)

N/A

Report date: 2026/01/14 10:59:53

Base Information

Drug NameGT-002(Glycotope)
Drug Alias NameGT002(Glycotope)GT-002GT002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsLy6/PLAUR domain-containing protein 3 modulators
TargetsLy6/PLAUR domain-containing protein 3
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGlycotope Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesPentixapharm AGMax Delbrück Center For Molecular Medicine
Inactive CompaniesGlycotope Gmbh
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A